

# John H Powers Iii

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4861418/publications.pdf>

Version: 2024-02-01

40  
papers

1,325  
citations

516710

16  
h-index

377865

34  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2213  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. <i>BMC Infectious Diseases</i> , 2015, 16, 1.	2.9	270
2	Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). <i>Clinical Infectious Diseases</i> , 2015, 61, 800-806.	5.8	206
3	Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020. <i>Annals of Internal Medicine</i> , 2021, 174, 1240-1251.	3.9	133
4	Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force. <i>Value in Health</i> , 2017, 20, 2-14.	0.3	109
5	Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administrationâ€ Approved Antibiotics, 2010â€2015. <i>Annals of Internal Medicine</i> , 2016, 165, 363.	3.9	81
6	Brucella arteritis: clinical manifestations, treatment, and prognosis. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 520-526.	9.1	54
7	Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. <i>Journal of Infectious Diseases</i> , 2019, 219, 1536-1544.	4.0	49
8	Issues in Noninferiority Trials: The Evidence in Communityâ€Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2008, 47, S108-S120.	5.8	47
9	Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 62, 603-607.	5.8	36
10	Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases. <i>Clinical Infectious Diseases</i> , 2016, 63, S52-S56.	5.8	32
11	Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI). <i>PLoS ONE</i> , 2018, 13, e0194180.	2.5	32
12	Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model. <i>BMC Infectious Diseases</i> , 2018, 18, 353.	2.9	29
13	Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PROâ€™) Scores in Influenza-Positive Patients. <i>Value in Health</i> , 2018, 21, 210-218.	0.3	27
14	Studying new antibiotics for multidrug resistant infections: are todayâ€™s patients paying for unproved future benefits?. <i>BMJ: British Medical Journal</i> , 2018, 360, k587.	2.3	24
15	Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011. <i>JAMA Internal Medicine</i> , 2017, 177, 1452.	5.1	22
16	PROPHETIC. <i>Chest</i> , 2020, 158, 2370-2380.	0.8	19
17	Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation. <i>Value in Health</i> , 2020, 23, 227-235.	0.3	16
18	Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) Instrument in Patients With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab517.	0.9	16

#	ARTICLE	IF	CITATIONS
19	Beyond Intuition: Patient Fever Symptom Experience. <i>Journal of Pain and Symptom Management</i> , 2013, 46, 807-816.	1.2	15
20	Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 243.	2.7	15
21	Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross-sectional study. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 462-473.	3.4	11
22	Recommendations for Improving the Design, Conduct, and Analysis of Clinical Trials in Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. <i>Clinical Infectious Diseases</i> , 2010, 51, S18-S28.	5.8	8
23	Accelerating innovation in rapid diagnostics and targeted antibacterials. <i>Nature Biotechnology</i> , 2015, 33, 589-590.	17.5	8
24	US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals. <i>JAMA Internal Medicine</i> , 2020, 180, 131.	5.1	8
25	Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: a report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group. <i>BMI Open</i> , 2021, 11, e051065.	1.9	7
26	Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain. <i>Contemporary Clinical Trials</i> , 2016, 50, 265-272.	1.8	6
27	Comparison of clinical characteristics of Zika and dengue symptomatic infections and other acute illnesses of unidentified origin in Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009133.	3.0	6
28	Assessment of the Perceived Acceptability of an Early Enrollment Strategy Using Advance Consent in Health Care-Associated Pneumonia. <i>JAMA Network Open</i> , 2018, 1, e185816.	5.9	5
29	Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone. <i>JAMA Internal Medicine</i> , 2019, 179, 719.	5.1	5
30	Comparison of the Impact of Zika and Dengue Virus Infection, and Other Acute Illnesses of Unidentified Origin on Cognitive Functions in a Prospective Cohort in Chiapas Mexico. <i>Frontiers in Neurology</i> , 2021, 12, 631801.	2.4	5
31	Scientific Evidence, Regulatory Decision Making, and Incentives for Therapeutics in Infectious Diseases: The Example of Cefiderocol. <i>Clinical Infectious Diseases</i> , 2020, 72, e1112-e1114.	5.8	4
32	Outcome Assessments in Clinical Trials of Cryptococcal Meningitis: Considerations on Use of Early Fungicidal Activity as a Potential Surrogate Endpoint for All-Cause Mortality. <i>Current Treatment Options in Infectious Diseases</i> , 2014, 6, 326-336.	1.9	3
33	Commentary: How to encourage more diagnostics for infectious diseases. <i>BMJ, The</i> , 2016, 354, i4744.	6.0	3
34	Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling. <i>Journal of General Internal Medicine</i> , 2020, 35, 377-379.	2.6	3
35	The Wrong Cure: Financial Incentives for Unimpressive New Antibiotics. <i>Journal of Infectious Diseases</i> , 2021, 223, 1506-1509.	4.0	3
36	Consensus on Language for Advance Informed Consent in Health Care-Associated Pneumonia Clinical Trials Using a Delphi Process. <i>JAMA Network Open</i> , 2020, 3, e205435.	5.9	2

#	ARTICLE	IF	CITATIONS
37	Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999–2018. Mayo Clinic Proceedings, 2020, 95, 2699-2703.	3.0	2
38	Determining the Infectious Potential of Individuals With Positive Reverse-Transcription Polymerase Chain Reaction Severe Acute Respiratory Syndrome Coronavirus 2 Tests. Clinical Infectious Diseases, 2021, 73, e3900-e3901.	5.8	2
39	Improving the Evidence for New Interventions in Infectious Diseases: Refocusing on Patients Instead of Pathogens and Direct Evidence for Added Patient Benefits. Clinical Infectious Diseases, 2021, 72, 1975-1978.	5.8	2
40	The Fight Against Multidrug-Resistant Bacteria. Annals of Internal Medicine, 2017, 166, 79.	3.9	0